Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CET

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
06:01a GLAXOSMITHKLINE : *rpt/ubs cuts glaxosmithkline price target to 1600 pence - 'ne..
12/06 GLAXOSMITHKLINE : *ubs cuts glaxosmithkline price target to 1600 pence - 'neutra..
12/06 ADAPTIMMUNE THERAPEUTICS : Announces Initiation of Myxoid/Round Cell Liposarcoma..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 Astex Joins the Dementia Discovery Fund as a Strategic Investor
12/05 INNOVIVA : Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 GlaxoSmithKline Says Limet To Step Down As CEO Of ViiV Venture
12/02 INNOVIVA : GSK files EU regulatory submission for once-daily closed triple combi..
12/02 GLAXOSMITHKLINE : NICE recommends first-of-its kind asthma treatment mepolizumab
More news
Sector news : Pharmaceuticals - NEC
04:49p Pharma, biotech stocks fall after Trump comment on drug prices
04:32p MYLAN : EpiPen maker Mylan to restructure and cut its workforce
04:19pDJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Spark Strengthens Case For Hemophilia Gene Therapy
12/05 GLAXOSMITHKLINE : Robust Pipeline Supports Its 5.5% Dividend Yield
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/02 5%+ DIVIDEND YIELD PORTFOLIO : Trump And The No Good, Very Bad Month (Nov 2016 R..
12/02 Glaxo files marketing application in Europe for inhaled triple combo COPD the..
Advertisement
Financials ( GBP)
Sales 2016 27 380 M
EBIT 2016 7 207 M
Net income 2016 2 570 M
Debt 2016 13 769 M
Yield 2016 5,55%
P/E ratio 2016 31,02
P/E ratio 2017 17,84
EV / Sales 2016 3,10x
EV / Sales 2017 2,88x
Capitalization 71 193 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,9  GBP
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC6.34%90 098
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results